Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 24, 2018. The report disseminates an LSE Announcement regarding ViiV Healthcare, a global specialist HIV company majority-owned by GSK. The filing details the presentation of 48-week results from the Phase III GEMINI 1 and GEMINI 2 studies at the 22nd International AIDS Conference in Amsterdam.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update and does not contain financial statements or quantitative financial performance data.
Material Changes and Clinical Results
The primary material update concerns the efficacy and safety of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a standard three-drug regimen (DTG + TDF/FTC) in treatment-naive HIV-1 infected adults.
- Primary Endpoint: The studies met the non-inferiority endpoint for plasma HIV-1 RNA <50 copies/mL at Week 48.
- Efficacy Rates: In a pooled analysis, 91% (655/716) of patients on the 2DR achieved viral suppression compared to 93% (669/717) on the three-drug regimen (adjusted difference -1.7%).
- Viral Load Consistency: Results were consistent across patients with high (>100,000 c/mL) and low (<=100,000 c/mL) baseline viral loads.
- Resistance: No patient experiencing virologic failure developed treatment-emergent resistance.
- Safety Profile: Drug-related adverse events were less frequent in the 2DR arm (18%) compared to the three-drug arm (24%). Withdrawal due to adverse events was 2% in both arms.
Guidance, Outlook, and Risks
Regulatory Outlook: ViiV Healthcare intends to seek regulatory approval for a fixed-dose combination of DTG and 3TC later in 2018. The 2DR is not yet approved by the US FDA.
Management Commentary: Management stated that the data supports rethinking the traditional three-drug approach, offering a valuable option that balances efficacy with improved tolerability and convenience for patients requiring lifelong therapy.
Risks and Contingencies: The filing includes standard forward-looking statement cautions, noting that actual results may differ due to risks described in GSK's 2017 Form 20-F. Specific drug safety warnings include hypersensitivity reactions, hepatotoxicity, immune reconstitution syndrome, and potential exacerbations of Hepatitis B upon discontinuation of lamivudine.
Investor Verification Checklist
- Verify the timeline for regulatory submission and potential approval of the DTG/3TC fixed-dose combination in the US and EU.
- Confirm the commercial impact of a two-drug regimen on the existing three-drug HIV treatment portfolio.
- Review the full prescribing information for Tivicay (dolutegravir) and Epivir (lamivudine) regarding drug interactions and safety warnings.
- Monitor the ongoing 148-week study duration for long-term safety and efficacy data beyond the 48-week mark.